Upstream Bio Finalizes Phase 3 Plans for Verekitug in Severe Asthma and CRSwNP
UPB is trading near its 52-week low of $5.85 (15% above the low).
Summary
Upstream Bio announced finalized Phase 3 development plans for verekitug in severe asthma and CRSwNP, including a 400mg quarterly regimen, ~1,500 patients across two placebo-controlled trials, and initiation expected in Q1 2027.
Key Events · Product Development and Regulatory · UPB
-
Phase 3 Plans Finalized
Upstream Bio will run one placebo-controlled Phase 3 trial each in severe asthma and CRSwNP, enrolling approximately 1,500 patients total, using a single 400mg subcutaneous dose of verekitug every 12 weeks.
-
FDA Alignment Achieved
The plans follow productive End-of-Phase 2 meetings with the FDA, de-risking the registrational path for verekitug in both indications.
-
Broad Patient Populations
Trials will enroll patients without restriction based on baseline biomarkers, supporting a broad label if successful.
-
Timeline Set
Phase 3 initiation is expected in Q1 2027, with potential BLA submission and U.S. launch as early as 2030.
Analysis · UPB · Life Sciences
Upstream Bio has locked in its pivotal Phase 3 strategy for verekitug following FDA End-of-Phase 2 meetings. The company will run one placebo-controlled trial in each indication — severe asthma and CRSwNP — enrolling roughly 1,500 patients total, using a single 400mg dose every 12 weeks. This removes a key uncertainty around the registrational path and sets a clear timeline: Phase 3 starts in Q1 2027, with potential BLA submission and launch as early as 2030. For a clinical-stage biotech with $261.3 million in cash, this is the roadmap that determines whether verekitug becomes a commercial product.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30% of the 1973 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, UPB was trading at $6.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $362.6M. The 52-week trading range was $5.85 to $33.68. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.